A NEW WAY FOR A NEW WORLD STARTS
TODAY
Evolution
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
Announced the launch of BRUKINSA® in India for the advanced treatment of Hematological Malignancies
Launches TEVIMBRA® in India for Non-Small Cell Lung Cancer and Esophageal Squamous Cell Carcinoma
Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma
IGI presented first-time safety and efficacy data for 20 heavily pre-treated patients from its Phase 1 (Part 1) study of ISB 2001 in an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA.
Became the first to launch a biosimilar of the popular anti-diabetic drug, Liraglutide, in India
Completed divestment of our 75% stake in GLS to Nirma Limited
Partnered with Pfizer to launch Abrocitinib in India under the brand name JABRYUS®
ISB 880, a partnered asset of Ichnos in immunology, progressed to Phase 1 studies initiated by our partner Almirall
Became the second Indian pharmaceutical Company to have Green House Gas (GHG) emission reduction targets approved by the SBTi initiative
Announced partnership with Cosmo for Winlevi® in Europe and South Africa
Ichnos received ‘orphan drug designation’ (ODD) from the US FDA for ISB 1442, a first-in-class biparatopic 2+1 BEAT® bispecific antibody and first-in-class Trispecific Antibody, ISB 2001
Ichnos enters into a licensing agreement for OX40 portfolio (ISB 830) with Astria Therapeutics
US FDA approves RYALTRIS®, our first global branded specialty drug for treating symptoms of seasonal allergic rhinitis
Became the first Indian pharmaceutical Company to raise a Sustainability-Linked Loan (SLL)
Continued to expand our Over-The-Counter Portfolio in the U.S. with the acquisition of approved ANDAs from Wockhardt Limited
GLS got listed on the Indian bourses, BSE and NSE
Launched FabiFlu® (Favipiravir) for mild to moderate COVID-19; exported to 24 countries by June 2021
Ichnos out-licensed its IL-1RAP antagonist, ISB 880, to Almirall SA for an upfront payment of EUR 20.8 Mn
Spun out its API arm, GLS
Created an innovation subsidiary focusing on immuno-Oncology, Ichnos Sciences, Inc. (Ichnos)
Signed an exclusive licensing agreement with Harbour Biomed in Greater China to develop, manufacture, and commercialize GBR 1302
Launched differentiated generics and introduced Ezetimibe, the generic version of Zetia in the U.S.
Commissioned a new manufacturing facility for injectables and oral solids in Monroe, North Carolina, U.S.
Out-licensed mPEGS-1 Inhibitor to Forest Labs for USD 15 Mn (upfront payment)
Out-licensed first New Biological Entity, GBR 500, to Sanofi-Aventis for USD 55 Mn (upfront and milestone payments)
Commissioned the third R&D center in Taloja, Maharashtra, India
Made our debut in the Oncology segment with the launch of Aprecap® (Aprepitant capsules) in India
Established our first R&D Center for New Biological Entities research in Switzerland
Signed our third Out-Licensing deal for Melogliptin with Merck KGaA for USD 31 Mn (total payment)
Launched front-end commercial sales with the first generic product in the U.S.
Set up our first manufacturing facility, built to US FDA specifications in Goa, India
Struck our second out-licensing deal for Oglemilast (GRC 3886) with Teijin Pharma, Japan, for USD 6 Mn (upfront payment)
Entered the European market through Glenmark Pharmaceuticals Europe Limited
Signed our first out-licensing agreement for Oglemilast (GRC 3886) with Forest Laboratories for USD 35 Mn (upfront and milestone payments)
Established North American subsidiary, Glenmark Pharmaceuticals, Inc.
Acquired API manufacturing plants at Ankleshwar, Gujarat
Commenced production of APIs at the Kurkumbh API manufacturing facility in Maharashtra
Went public with a market capitalization of USD 40 Mn on the Indian bourses, NSE & BSE
Set up a second R&D center at Mahape, Navi Mumbai, to focus on Novel Chemical Entities
Set up our first Research and Development center at Sinnar
Entered the Respiratory segment with the launch of Ascoril®, a cough expectorant
Commissioned the first manufacturing unit in Nashik
Commenced operations in Russia and CIS
Forayed into Dermatology therapy with the launch of ‘Candid Cream’
Mr. Gracias Saldanha (Founder Emeritus) laid the foundation stone of Glenmark